Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$56.78 USD
-0.18 (-0.32%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $56.74 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$56.78 USD
-0.18 (-0.32%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $56.74 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
by Zacks Equity Research
Ultragenyx (RARE) gets FDA approval forDojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders.
Ultragenyx Gets FDA Nod for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) gets FDA approval for the label expansion of Crysvita into tumor-induced osteomalacia.
Utragenyx Shares Soar Above 60% YTD on Pipeline Developments
by Zacks Equity Research
Ultragenyx's (RARE) shares rise more than 60% year to date on various positive pipeline developments.
Why Is Ultragenyx (RARE) Up 10.7% Since Last Earnings Report?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -27.50% and -3.70%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Ultragenyx Pharmaceutical Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Ultragenyx Pharmaceutical
Amarin's (AMRN) Q1 Loss In Line With Estimates, Sales Beat
by Zacks Equity Research
Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa.
Will Soliris & Ultomiris Drive Alexion's (ALXN) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.
Perrigo (PRGO) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Perrigo (PRGO) reports decent first-quarter 2019 results. The addition of products following Ranir acquisition and stock piling due to COVID-19 boosts sales in the quarter.
Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat
by Zacks Equity Research
Alkermes (ALKS) beats earnings and sales estimates for the first quarter of 2020. The company withdraws its previously provided outlook for 2020 amid uncertainty related to coronavirus.
Is a Surprise Coming for Ultragenyx (RARE) This Earnings Season?
by Zacks Equity Research
Ultragenyx (RARE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Down 31.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4
by Zacks Equity Research
Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
Ultragenyx Provides Preliminary Crysvita 2019 Revenues
by Zacks Equity Research
Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.
Ultragenyx's Gene Therapy Positive in Genetic Disorder Study
by Zacks Equity Research
Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.
Ultragenyx (RARE) Up 13.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -14.62% and -9.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA
by Zacks Equity Research
Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
Ultragenyx to Submit sBLA for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
by Zacks Equity Research
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.